vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and NEOGENOMICS INC (NEO). Click either name above to swap in a different company.
NEOGENOMICS INC is the larger business by last-quarter revenue ($186.7M vs $185.2M, roughly 1.0× AMICUS THERAPEUTICS, INC.). AMICUS THERAPEUTICS, INC. runs the higher net margin — 0.9% vs -57.9%, a 58.8% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 11.1%). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 6.5%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.
FOLD vs NEO — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $186.7M |
| Net Profit | $1.7M | $-108.0M |
| Gross Margin | 85.7% | 43.3% |
| Operating Margin | 8.6% | 46.9% |
| Net Margin | 0.9% | -57.9% |
| Revenue YoY | 23.7% | 11.1% |
| Net Profit YoY | -88.5% | 42.0% |
| EPS (diluted) | $0.00 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $186.7M | ||
| Q4 25 | $185.2M | $190.2M | ||
| Q3 25 | $169.1M | $187.8M | ||
| Q2 25 | $154.7M | $181.3M | ||
| Q1 25 | $125.2M | $168.0M | ||
| Q4 24 | $149.7M | $172.0M | ||
| Q3 24 | $141.5M | $167.8M | ||
| Q2 24 | $126.7M | $164.5M |
| Q1 26 | — | $-108.0M | ||
| Q4 25 | $1.7M | — | ||
| Q3 25 | $17.3M | $-27.1M | ||
| Q2 25 | $-24.4M | $-45.1M | ||
| Q1 25 | $-21.7M | $-25.9M | ||
| Q4 24 | $14.7M | — | ||
| Q3 24 | $-6.7M | $-17.7M | ||
| Q2 24 | $-15.7M | $-18.6M |
| Q1 26 | — | 43.3% | ||
| Q4 25 | 85.7% | 43.8% | ||
| Q3 25 | 88.5% | 42.8% | ||
| Q2 25 | 90.2% | 42.6% | ||
| Q1 25 | 90.7% | 43.6% | ||
| Q4 24 | 90.1% | 44.9% | ||
| Q3 24 | 90.6% | 44.6% | ||
| Q2 24 | 91.1% | 44.1% |
| Q1 26 | — | 46.9% | ||
| Q4 25 | 8.6% | -7.1% | ||
| Q3 25 | 20.3% | -14.4% | ||
| Q2 25 | -6.1% | -26.3% | ||
| Q1 25 | -6.3% | -16.6% | ||
| Q4 24 | 10.7% | -10.7% | ||
| Q3 24 | 15.3% | -12.6% | ||
| Q2 24 | 11.8% | -13.3% |
| Q1 26 | — | -57.9% | ||
| Q4 25 | 0.9% | — | ||
| Q3 25 | 10.2% | -14.4% | ||
| Q2 25 | -15.8% | -24.9% | ||
| Q1 25 | -17.3% | -15.4% | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | -4.8% | -10.5% | ||
| Q2 24 | -12.4% | -11.3% |
| Q1 26 | — | $-0.13 | ||
| Q4 25 | $0.00 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $-0.08 | — | ||
| Q1 25 | $-0.07 | — | ||
| Q4 24 | $0.05 | — | ||
| Q3 24 | $-0.02 | — | ||
| Q2 24 | $-0.05 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $146.1M |
| Total DebtLower is stronger | $392.7M | — |
| Stockholders' EquityBook value | $274.2M | $828.8M |
| Total Assets | $949.9M | $1.3B |
| Debt / EquityLower = less leverage | 1.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $146.1M | ||
| Q4 25 | $293.5M | $159.6M | ||
| Q3 25 | $263.8M | $164.1M | ||
| Q2 25 | $231.0M | $154.7M | ||
| Q1 25 | $250.6M | $346.2M | ||
| Q4 24 | $249.9M | $367.0M | ||
| Q3 24 | $249.8M | $362.0M | ||
| Q2 24 | $260.1M | $355.1M |
| Q1 26 | — | — | ||
| Q4 25 | $392.7M | $341.9M | ||
| Q3 25 | $392.0M | — | ||
| Q2 25 | $391.3M | — | ||
| Q1 25 | $390.7M | — | ||
| Q4 24 | $390.1M | $541.1M | ||
| Q3 24 | $389.5M | — | ||
| Q2 24 | $388.9M | — |
| Q1 26 | — | $828.8M | ||
| Q4 25 | $274.2M | $836.6M | ||
| Q3 25 | $230.4M | $838.3M | ||
| Q2 25 | $204.3M | $854.0M | ||
| Q1 25 | $193.6M | $888.3M | ||
| Q4 24 | $194.0M | $902.3M | ||
| Q3 24 | $178.8M | $908.2M | ||
| Q2 24 | $132.5M | $915.9M |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $949.9M | $1.4B | ||
| Q3 25 | $868.8M | $1.4B | ||
| Q2 25 | $815.3M | $1.4B | ||
| Q1 25 | $789.8M | $1.6B | ||
| Q4 24 | $785.0M | $1.6B | ||
| Q3 24 | $786.6M | $1.6B | ||
| Q2 24 | $749.5M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 0.41× | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.02× | — | ||
| Q4 24 | 2.01× | 0.60× | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 2.93× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $-8.1M |
| Free Cash FlowOCF − Capex | $16.0M | — |
| FCF MarginFCF / Revenue | 8.6% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 9.62× | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-8.1M | ||
| Q4 25 | $16.3M | $1.3M | ||
| Q3 25 | $35.7M | $8.9M | ||
| Q2 25 | $-26.5M | $20.3M | ||
| Q1 25 | $7.8M | $-25.3M | ||
| Q4 24 | $-3.9M | $9.8M | ||
| Q3 24 | $-23.0M | $9.2M | ||
| Q2 24 | $22.7M | $13.9M |
| Q1 26 | — | — | ||
| Q4 25 | $16.0M | $-6.5M | ||
| Q3 25 | $35.3M | $570.0K | ||
| Q2 25 | $-28.9M | $14.0M | ||
| Q1 25 | $7.5M | $-29.8M | ||
| Q4 24 | $-4.2M | $-1.8M | ||
| Q3 24 | $-23.3M | $-1.6M | ||
| Q2 24 | $21.6M | $814.0K |
| Q1 26 | — | — | ||
| Q4 25 | 8.6% | -3.4% | ||
| Q3 25 | 20.9% | 0.3% | ||
| Q2 25 | -18.7% | 7.7% | ||
| Q1 25 | 6.0% | -17.8% | ||
| Q4 24 | -2.8% | -1.0% | ||
| Q3 24 | -16.5% | -0.9% | ||
| Q2 24 | 17.0% | 0.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 4.1% | ||
| Q3 25 | 0.2% | 4.4% | ||
| Q2 25 | 1.6% | 3.5% | ||
| Q1 25 | 0.2% | 2.7% | ||
| Q4 24 | 0.2% | 6.7% | ||
| Q3 24 | 0.3% | 6.4% | ||
| Q2 24 | 0.9% | 8.0% |
| Q1 26 | — | — | ||
| Q4 25 | 9.62× | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
NEO
Segment breakdown not available.
